EFFECT OF TREATMENT OF HYPERURICEMIA WITH FEBUXOSTAT IN HYPERTENSIVE PATIENTS WITH CHRONIC HEART FAILURE AND CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Naka, T. [1 ]
Sumiyoshi, A. [2 ]
Ando, T. [2 ]
Shibuya, M. [2 ]
Masuyama, T. [2 ]
机构：
[1] Kaizuka City Hosp, Dept Internal Med, Kaizuka, Japan
[2] Hyogo Coll Med, Dept Internal Med, Cardiovasc Div, Nishinomiya, Hyogo, Japan
来源：
CARDIOLOGY | 2015年 / 131卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
135
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [31] Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia
    Takata, Tomoaki
    Taniguchi, Sosuke
    Mae, Yukari
    Kageyama, Kana
    Fujino, Yudai
    Iyama, Takuji
    Hikita, Katsuya
    Sugihara, Takaaki
    Isomoto, Hajime
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [32] Febuxostat for the chronic management of hyperuricemia in patients with gout
    Chinchilla, Sandra Pamela
    Urionaguena, Irati
    Perez-Ruiz, Fernando
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 665 - 673
  • [33] URATE LOWERING EFFECT OF FEBUXOSTAT AMONG PATIENTS WITH ASYMPTOMATIC HYPERURICEMIA IN ADVANCED CHRONIC KIDNEY DISEASE: A CASE-SERIES
    Erika Bianca, Villazor-Isidro
    Christine Joy, Pega-Flores
    John Carlo, Brojan
    Paul, Santos-Estrella
    Jeanne, Bayaca
    NEPHROLOGY, 2014, 19 : 74 - 75
  • [34] Drug treatment of heart failure in chronic kidney disease
    Marx, Nikolaus
    INTERNIST, 2020, 61 (04): : 357 - 361
  • [35] OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Zachariah, Donah
    Kaira, Philip A.
    Kaira, Paul R.
    JOURNAL OF RENAL CARE, 2009, 35 (01) : 2 - 10
  • [36] CHRONIC KIDNEY DISEASE IN THE EVALUATION OF COMORBIDITY IN PATIENTS WITH CHRONIC HEART FAILURE
    Efremova, E.
    Shutov, A.
    ATHEROSCLEROSIS, 2020, 315 : E263 - E264
  • [37] Xanthine metabolism in chronic heart failure patients with chronic kidney disease
    Smolianyk, K. Kateryna
    Bilchenko, A.
    Kolomiiets, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 138 - 138
  • [38] Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
    Mari Katsumata
    Nobuhito Hirawa
    Koichiro Sumida
    Minako Kagimoto
    Yosuke Ehara
    Yuki Okuyama
    Megumi Fujita
    Akira Fujiwara
    Mayumi Kobayashi
    Yusuke Kobayashi
    Yuichiro Yamamoto
    Sanae Saka
    Keisuke Yatsu
    Tetsuya Fujikawa
    Yoshiyuki Toya
    Gen Yasuda
    Kouichi Tamura
    Satoshi Umemura
    Clinical and Experimental Nephrology, 2017, 21 : 858 - 865
  • [39] Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
    Katsumata, Mari
    Hirawa, Nobuhito
    Sumida, Koichiro
    Kagimoto, Minako
    Ehara, Yosuke
    Okuyama, Yuki
    Fujita, Megumi
    Fujiwara, Akira
    Kobayashi, Mayumi
    Kobayashi, Yusuke
    Yamamoto, Yuichiro
    Saka, Sanae
    Yatsu, Keisuke
    Fujikawa, Tetsuya
    Toya, Yoshiyuki
    Yasuda, Gen
    Tamura, Kouichi
    Umemura, Satoshi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (05) : 858 - 865
  • [40] Reversibility of chronic heart failure symptoms in chronic kidney disease patients
    Belov, V. V.
    Ilyicheva, O. E.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2007, 6 (01): : 68 - 72
12345